Northwest Biotherapeutics, Inc. (NWBO)
|Address:4800 Montgomery Ln Ste 800
Bethesda, Maryland 20814-3676
|Phone||240 497 9024|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.
The company was founded in 1996 and is headquartered in Bethesda, Maryland.
|Linda F. Powers J.D.||Chairperson, Chief Executive Officer, President, Chief Financial Officer and Chief Accounting Officer|
|Dr. Alton L. Boynton||Founder, Chief Scientific Officer, Secretary and Director|
|Dr. Marnix L. Bosch M.B.A., Ph.D., MBA||Chief Technical Officer|
|Leslie J. Goldman||Senior Vice President and General Counsel|
|Jean M. Davis||Chief Information Officer|
|David Innes||Vice President of Investor Relations|
|Pankaj R. Shah C.A., CPA||Financial Controller|
Latest SEC Filings
|May 24, 2021||8-K||Current report|
|May 17, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Apr 16, 2021||DEF 14A||Other definitive proxy statements|
|Mar 31, 2021||10-K||Annual report [Section 13 and 15(d), not S-K Item 405]|
|Mar 5, 2021||8-K||Current report|
|Jan 26, 2021||8-K||Current report|
|Jan 19, 2021||4||Statement of changes in beneficial ownership of securities|
|Jan 15, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 10, 2020||NT 10-Q||Notification of inability to timely file Form 10-Q or 10-QSB|
|Nov 2, 2020||8-K||Current report|
|View All SEC filings|